Possible Pharmacodynamic and Pharmacokinetic Drug-Drug Interactions That Are Likely to Be Clinically Relevant and/or Frequent in Bipolar Disorder

Mood Disorders (E Baca-Garcia, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Mood Disorders

Abstract

Purpose of Review

Patients with bipolar disorder are frequently treated with polypharmacy. This article should provide clinicians with an understanding of how polypharmacy can contribute to pharmacokinetic and pharmacodynamic drug-drug interactions (DDIs).

Recent Findings

The pharmacokinetics and pharmacodynamics of lithium and other mood stabilizers (valproate, lamotrigine, carbamazepine, oxcarbazepine, and eslicarbazepine), antipsychotics, and selective serotonin reuptake inhibitors (SSRIs) were reviewed and summarized in the first four tables describing their pharmacokinetic and pharmacodynamic mechanisms.

Summary

Four tables summarized the DDIs which are likely to be clinically relevant in adults with bipolar disorder: two for mania treatments (with and without carbamazepine), one for maintenance treatments, and one for depression treatments. The purpose is to be practical, helping clinicians pay attention to and manage polypharmacy, avoiding adverse drug reactions (ADRs) in patients with bipolar disorder, including both the frequent ADRs and those rare but potentially lethal ADRs. Future articles should improve these tables.

Keywords

Anticonvulsant Antidepressant Antipsychotic Bipolar disorder Drug interactions Lithium 

Notes

Acknowledgements

The authors acknowledge Lorraine Maw, M.A., at the University of Kentucky Mental Health Research Center at Eastern State Hospital, Lexington, KY, USA, who helped in editing this article.

Compliance with Ethical Standards

Conflict of Interest

The authors declare they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    •• Fornaro M, De Berardis D, Koshy AS, Perna G, Valchera A, Vancampfort D, et al. Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review. Neuropsychiatr Dis Treat. 2016;31(12):719–35. Systematic review of the high frequency of polypharmacy in bipolar disorder. CrossRefGoogle Scholar
  2. 2.
    Goldberg JF, Brooks JO 3rd, Kurita K, Hoblyn JC, Ghaemi SN, Perlis RH, et al. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry. 2009;70(2):155–62.  https://doi.org/10.4088/JCP.08m04301.CrossRefPubMedGoogle Scholar
  3. 3.
    Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30(6):495–553.  https://doi.org/10.1177/0269881116636545.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1–44.  https://doi.org/10.1111/bdi.12025.CrossRefPubMedGoogle Scholar
  5. 5.
    Fountoulakis KN, Grunze H, Vieta E, Young A, Yatham L, Blier P, et al. The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines. Int J Neuropsychopharmacol. 2017;20(2):180–95.  https://doi.org/10.1093/ijnp/pyw109.PubMedGoogle Scholar
  6. 6.
    Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14(3):154–219.  https://doi.org/10.3109/15622975.2013.770551.CrossRefPubMedGoogle Scholar
  7. 7.
    National Institute for Health and Clinical Excellence. Bipolar disorder (update): the management of bipolar disorder in adults, children and adolescents in primary and secondary care. (Clinical Guideline 185.) 2014. http://guidance.nice.org.uk/CG185.
  8. 8.
    Malhi GS, Bassett D, Boyce P, Bryant R, Fitzgerald PB, Fritz K, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49(12):1087–206.  https://doi.org/10.1177/0004867415617657.CrossRefPubMedGoogle Scholar
  9. 9.
    Ostacher MJ, Tandon R, Suppes T. Florida best practice psychotherapeutic medication guidelines for adults with bipolar disorder: a novel, practical, patient-centered guide for clinicians. J Clin Psychiatry. 2016;77(7):920–6.  https://doi.org/10.4088/JCP.15cs09841.CrossRefPubMedGoogle Scholar
  10. 10.
    Kanba S, Kato T, Terao T, Yamada K, Committee for Treatment Guidelines of Mood Disorders, Japanese Society of Mood Disorders, 2012. Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012. Psychiatry Clin Neurosci. 2013;67(5):285–300.  https://doi.org/10.1111/pcn.12060.CrossRefPubMedGoogle Scholar
  11. 11.
    de Leon J. A critical commentary on the 2017 AGNP consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology. Pharmacopsychiatry. 2018;51(1-02):63-68.  https://doi.org/10.1055/s-0043-117891.PubMedGoogle Scholar
  12. 12.
    Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007;100(1):4–22.  https://doi.org/10.1111/j.1742-7843.2007.00017.x.CrossRefPubMedGoogle Scholar
  13. 13.
    de Leon J, Santoro V, D'Arrigo C, Spina E. Interactions between antiepileptics and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2012;8(3):311–34.  https://doi.org/10.1517/17425255.2012.660918.CrossRefPubMedGoogle Scholar
  14. 14.
    • Spina E, de Leon J. Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2014;10(5):721–46. First attempt to explore pharmacokinetic and pharmacodynamic drug-drug interactions between new antipsychotics and new antidepressants.  https://doi.org/10.1517/17425255.2014.885504.CrossRefPubMedGoogle Scholar
  15. 15.
    • Italiano D, Spina E, de Leon J. Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants. Expert Opin Drug Metab Toxicol. 2014;10(11):1457–89. First attempt to explore pharmacokinetic and pharmacodynamic drug-drug interactions between antiepileptic and antidepressant drugs.  https://doi.org/10.1517/17425255.2014.956081.CrossRefPubMedGoogle Scholar
  16. 16.
    Spina E, Hiemke C, de Leon J. Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2016;12(4):407–22.  https://doi.org/10.1517/17425255.2016.1154043.CrossRefPubMedGoogle Scholar
  17. 17.
    • Spina E, Pisani F, de Leon J. Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. Pharmacol Res. 2016;106:72–86. This review article includes tables with a summary of dose correction factors for the pharmacokinetic drug-drug interactions used in the tables of this new article.  https://doi.org/10.1016/j.phrs.2016.02.014.CrossRefPubMedGoogle Scholar
  18. 18.
    •• Spina E, de Leon J. Potentially clinically relevant pharmacodynamics interactions between antiepileptic drugs and psychotropic drugs: an update. Curr Pharm Des. 2017;23  https://doi.org/10.2174/1381612823666170809102258. First attempt to explore pharmacodynamic drug-drug interactions of antiepileptic drugs with the main psychiatric drugs.
  19. 19.
    Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1-02):e1.  https://doi.org/10.1055/s-0043-116492.PubMedGoogle Scholar
  20. 20.
    Lana F, Martí-Bonany J, Fuster J, de Leon J. Reduction in serum concentration of valproic acid secondary to the intake of ibuprofen as an example of valproic acid auto-induction metabolism. Actas Esp Psiquiatr. 2016;44(4):136–44.PubMedGoogle Scholar
  21. 21.
    de Leon J. The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: a summary of the current state for clinicians. Rev Psiquiatr Salud Ment. 2015;8(2):97–115.  https://doi.org/10.1016/j.rpsm.2014.10.006.CrossRefPubMedGoogle Scholar
  22. 22.
    de Leon J. The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part II: pharmacological issues and further understanding. Rev Psiquiatr Salud Ment. 2015;8(3):167–88.  https://doi.org/10.1016/j.rpsm.2014.10.005.CrossRefPubMedGoogle Scholar
  23. 23.
    Zamani A, Omrani GR, Nasab MM. Lithium’s effect on bone mineral density. Bone. 2009;44(2):331–4.  https://doi.org/10.1016/j.bone.2008.10.001.CrossRefPubMedGoogle Scholar
  24. 24.
    Jin Y, Xu L, Hu X, Liao S, Pathak JL, Liu J. Lithium chloride enhances bone regeneration and implant osseointegration in osteoporotic conditions. J Bone Miner Metab. 2017;35(5):497–503.CrossRefGoogle Scholar
  25. 25.
    Finley PR. Drug interactions with lithium: an update. Clin Pharmacokinet. 2016;55(8):925–41.  https://doi.org/10.1007/s40262-016-0370-y.CrossRefPubMedGoogle Scholar
  26. 26.
    • Roux M, Dosseto A. From direct to indirect lithium targets: a comprehensive review of omics data. Metallomics. 2017;9(10):1326–51.  https://doi.org/10.1039/c7mt00203c. Comprehensive update of complex lithium pharmacodynamic actions. CrossRefPubMedGoogle Scholar
  27. 27.
    Jackson J, McCollum B, Ognibene J, Diaz FJ, de Leon J. Three patients needing high doses of valproic acid to get therapeutic concentrations. Case Rep Psychiatry. 2015;2015(542862):1–12.  https://doi.org/10.1155/2015/542862.Google Scholar
  28. 28.
    Schoretsanitis G, Spina E, Hiemke C, de Leon J. A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. Expert Rev Clin Pharmacol. 2017;10(9):965–81.  https://doi.org/10.1080/17512433.2017.1345623.CrossRefPubMedGoogle Scholar
  29. 29.
    • Ogawa Y, Tajika A, Takeshima N, Hayasaka Y, Furukawa TA. Mood stabilizers and antipsychotics for acute mania: a systematic review and meta-analysis of combination/augmentation therapy versus monotherapy. CNS Drugs. 2014;28(11):989–1003. Systematic review of combined therapy versus monotherapy in mania.  https://doi.org/10.1007/s40263-014-0197-8.CrossRefPubMedGoogle Scholar
  30. 30.
    • Glue P, Herbison P. Comparative efficacy and acceptability of combined antipsychotics and mood stabilizers versus individual drug classes for acute mania: network meta-analysis. Aust N Z J Psychiatry. 2015;49(12):1215–20. Systematic review of combined therapy versus monotherapy in mania.  https://doi.org/10.1177/0004867415614109.CrossRefPubMedGoogle Scholar
  31. 31.
    • Galling B, Garcia MA, Osuchukwu U, Hagi K, Correll CU. Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis. Expert Opin Drug Saf. 2015;14(8):1181–99. Systematic review of combined therapy versus monotherapy in mania or bipolar depression.  https://doi.org/10.1517/14740338.2015.1053457.CrossRefPubMedGoogle Scholar
  32. 32.
    Lin D, Mok H, Yatham LN. Polytherapy in bipolar disorder. CNS Drugs. 2006;20(1):29–42.  https://doi.org/10.2165/00023210-200620010-00003.CrossRefPubMedGoogle Scholar
  33. 33.
    Geoffroy PA, Etain B, Henry C, Bellivier F. Combination therapy for manic phases: a critical review of a common practice. CNS Neurosci Ther. 2012;18(12):957–64.  https://doi.org/10.1111/cns.12017.CrossRefPubMedGoogle Scholar
  34. 34.
    Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry. 2003;182(02):141–7.  https://doi.org/10.1192/bjp.182.2.141.CrossRefPubMedGoogle Scholar
  35. 35.
    de Leon J. False-negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology: part II: focus on bipolar disorder. J Clin Psychopharmacol. 2014;34(3):291–6.  https://doi.org/10.1097/JCP.0000000000000115.CrossRefPubMedGoogle Scholar
  36. 36.
    de Leon J. False-negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology. Part I: focus on epilepsy. J Clin Psychopharmacol. 2014;34(2):177–83.  https://doi.org/10.1097/JCP.0000000000000093.CrossRefPubMedGoogle Scholar
  37. 37.
    Tohen M, Bowden CL, Smulevich AB, Bergstrom R, Quinlan T, Osuntokun O, et al. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br J Psychiatry. 2008;192(2):135–43.  https://doi.org/10.1192/bjp.bp.107.041301.CrossRefPubMedGoogle Scholar
  38. 38.
    Katagiri H, Takita Y, Tohen M, Higuchi T, Kanba S, Takahashi M. Safety and efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic/mixed episodes for Japanese patients with bipolar I disorder. Curr Med Res Opin. 2012;28(5):701–13.  https://doi.org/10.1185/03007995.2012.666961.CrossRefPubMedGoogle Scholar
  39. 39.
    Weisler RH, Kalali AH, Cutler AJ, Gazda TD, Ginsberg L. Safety of carbamazepine extended-release capsules used in combination with other psychotropic medications for the treatment of bipolar I disorder. Psychiatry (Edgmont). 2008;5(5):49–60.Google Scholar
  40. 40.
    Vieta E, Günther O, Locklear J, Ekman M, Miltenburger C, Chatterton ML, et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2011;14(8):1029–49.  https://doi.org/10.1017/S1461145711000885.CrossRefPubMedGoogle Scholar
  41. 41.
    Popovic D, Reinares M, Amann B, Salamero M, Vieta E. Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder. Psychopharmacology. 2011;213(4):657–67.  https://doi.org/10.1007/s00213-010-2056-8.CrossRefPubMedGoogle Scholar
  42. 42.
    Buoli M, Serati M, Altamura AC. Is the combination of a mood stabilizer plus an antipsychotic more effective than mono-therapies in long-term treatment of bipolar disorder? A systematic review. J Affect Disord. 2014;152-154:12–8.  https://doi.org/10.1016/j.jad.2013.08.024.CrossRefPubMedGoogle Scholar
  43. 43.
    Yatham LN, Beaulieu S, Schaffer A, Kauer-Sant'Anna M, Kapczinski F, Lafer B, et al. Optimal duration of risperidone or olanzapine adjunctive therapy to moo stabilizer following remission of a manic episode: a CANMAT randomized double-blind trial. Mol Psychiatry. 2016;21(8):1050–6.  https://doi.org/10.1038/mp.2015.158.CrossRefPubMedGoogle Scholar
  44. 44.
    Zhang Y, Yang H, Yang S, Liang W, Dai P, Wang C, et al. Antidepressants for bipolar disorder: a meta-analysis of randomized, double-blind, controlled trials. Neural Regen Res. 2013;8(31):2962–74.  https://doi.org/10.3969/j.issn.1673-5374.2013.31.009.PubMedPubMedCentralGoogle Scholar
  45. 45.
    • McGirr A, Vöhringer PA, Ghaemi SN, Lam RW, Yatham LN. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry. 2016;3(12):1138–46. Systematic review of combined therapy versus monotherapy in bipolar depression.  https://doi.org/10.1016/S2215-0366(16)30264-4.CrossRefPubMedGoogle Scholar
  46. 46.
    Köhler S, Gaus S, Bschor T. The challenge of treatment in bipolar depression: evidence from clinical guidelines, treatment recommendations and complex treatment situations. Pharmacopsychiatry. 2014;47(2):53–9.  https://doi.org/10.1055/s-0033-1364004.CrossRefPubMedGoogle Scholar
  47. 47.
    Ketter TA, Miller S, Dell'Osso B, Calabrese JR, Frye MA, Citrome L. Balancing benefits and harms of treatments for acute bipolar depression. J Affect Disord. 2014;169(Suppl 1):S24–33.  https://doi.org/10.1016/S0165-0327(14)70006-0.CrossRefPubMedGoogle Scholar
  48. 48.
    de Leon J. Evidence-based medicine versus personalized medicine: are they enemies? J Clin Psychopharmacol. 2012;32(2):153–64.  https://doi.org/10.1097/JCP.0b013e3182491383.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.University of Kentucky Mental Health Research Center at Eastern State HospitalLexingtonUSA
  2. 2.Psychiatry and Neurosciences Research Group (CTS-549), Institute of NeurosciencesUniversity of GranadaGranadaSpain
  3. 3.Biomedical Research Centre in Mental Health Net (CIBERSAM), Santiago Apóstol HospitalUniversity of the Basque CountryVitoriaSpain
  4. 4.Department of Clinical and Experimental MedicineUniversity of MessinaMessinaItaly

Personalised recommendations